This breakthrough offers new hope for millions of patients struggling with diabetes-related kidney complications, providing a more effective treatment option to improve long-term health outcomes
As with other GLP-1 agonists, the medication helps regulate blood sugar levels by triggering insulin release and limiting the release of glucagon
This injectable medication is classified as a Glucagon-Like Peptide 1 (GLP-1) receptor agonist, acting similarly to the hormone GLP-1
Introduction Diabetes has emerged as an increasingly critical global health issue
Yes by reducing obesity, there is a correlation to the reduction in the prevalence of cardiovascular disease but there is still not enough cost-effectiveness for it to make sense for employers and insurance companies to cover medications like Semaglutide when used for weight-loss purposes
However, if blood sugar drops too low (a condition called hypoglycemia), it can trigger symptoms like sweating, dizziness, and heart palpitations